Patient Care Deteriorates After Private Equity Acquisition of Hospitals
Study supports other research showing worse outcomes after private equity acquisition
Related Articles
SAMBA and ASRA Webinar: Pocus
Moderator: Kumar Belani, MD Presenter: Siva Arumugam, MD, FASA and Anahi Perlas, MD,
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Practical Guide to Multiomics Big Data Sources
This Guide to Statistics and Methods explores the benefits for disease detection and treatment of using big data sources, such as large-scale biobanks, and discusses…
Over 18 000 doctors urge Senate to reject Robert F Kennedy Jr as health secretary
More than 18 000 US doctors have signed a letter calling on the Senate to reject Robert F Kennedy Jr as the federal secretary of…
Limitations of athlete-exposures as a construct for comparisons of injury rates by gender/sex: a narrative review
High rates of anterior cruciate ligament (ACL) injuries in girls’ and women’s sports have garnered significant attention from researchers, sport organisations and the media. Gender/sex…
Mayo Clinic Cardiovascular Education
Mayo Clinic is committed to taking care of our patients, learners and staff. Mayo Clinic Department of Cardiovascular Medicine education is actively planning livestream courses,…
SCLC: Treatment Overview and Treatment Landscape of Limited Stage – 2024 Lung Cancer OncTalk
The 2024 Lung Cancer OncTalk was a live, virtual, interactive patient education event presented in December 2024 and led by Dr. Ibiayi Dagogo-Jack. It includ…
CDC Grant Funds Initiatives for Breast Cancer Patients
The five-year, $2.3 million grant from the Centers for Disease Control and Prevention will seek to improve equitable access to care, quality of life and…
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer | Pfizer
C linically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor If approved, sasanlimab would…
Financial Toxicity in Cancer Care: Where Are We, and How Did We Get Here? Introduction to a Special Series | JCO Oncology Practice
The first academic article using the term “financial toxicity” was published in 2013, 1 which catalyzed the growth of an emerging field of research and…
